Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models

被引：2
|
作者：
Han, Lina [1 ]
Zhang, Qi [1 ]
Shi, Ce [2 ]
Cavazos, Antonio [1 ]
Ruvolo, Vivian [1 ]
Leverson, Joel [3 ]
Monique, Dail [4 ]
Phillips, Darren C. [3 ]
Chen, Jun [3 ]
Jin, Sha S. [3 ]
Jacamo, Rodrigo Omar [1 ]
Daver, Naval [1 ]
Jabbour, Elias J. [1 ]
Kantarjian, Hagop M. [1 ]
Andreeff, Michael [1 ]
Sampath, Deepak [4 ]
Konopleva, Marina [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Harbin Med Univ, Affiliated Hosp 1, Dept Leukemia, Harbin, Peoples R China
[3] AbbVie Inc, N Chicago, IL USA
[4] Genentech Inc, San Francisco, CA USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.97.97
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
97
引用
收藏
页数：5
相关论文
共 45 条
  • [1] Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models
    Han, Lina
    Zhang, Qi
    Shi, Ce
    Cavazos, Antonio
    Ruvolo, Vivian R.
    Leverson, Joel D.
    Dail, Monique
    Phillips, Darren C.
    Chen, Jun
    Jin, Sha S.
    Jacamo, Rodrigo
    Daver, Naval
    Jabbour, Elias
    Kantarjian, Hagop M.
    Andreeff, Michael
    Sampath, Deepak
    Konopleva, Marina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S282 - S282
  • [2] Concomitantly Targeting BCL-2 with Venetoclax (ABT-199/GDC-0199) and MAPK Signaling with Cobimetinib (GDC-0973) in Acute Myeloid Leukemia Models
    Han, Lina
    Zhang, Qi
    Shi, Ce
    Leverson, Joel
    Dail, Monique
    Phillips, Darren C.
    Chen, Jun
    Jin, Sha S.
    Jacamo, Rodrigo Omar
    Daver, Naval
    Jabbour, Elias J.
    Kantarjian, Hagop M.
    Andreeff, Michael
    Sampath, Deepak
    Konopleva, Marina
    BLOOD, 2015, 126 (23)
  • [3] Correlative biomarkers of clinical activity of the BCL-2 inhibitor, venetoclax (ABT-199/GDC-0199), in acute myeloid leukemia patients
    Popovic, Relja
    Daver, Naval
    Ruvolo, Vivian
    Chen, Ken
    Wang, Zixing
    Huang, Xin
    Mabry, Mack
    Potluri, Jalaja
    McKeegan, Evelyn
    Konopleva, Marina
    Chyla, Brenda J.
    CANCER RESEARCH, 2016, 76
  • [4] A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)
    Konopleva, Marina
    Pollyea, Daniel A.
    Potluri, Jalaja
    Chyla, Brenda J.
    Busman, Todd
    McKeegan, Evelyn
    Salem, Ahmed
    Zhu, Ming
    Ricker, Justin L.
    Blum, William
    DiNardo, Courtney D.
    Dunbar, Martin
    Kirby, Rachel
    Falotico, Nancy
    Leverson, Joel D.
    Humerickhouse, Rod A.
    Mabry, Mack
    Stone, Richard M.
    Kantarjian, Hagop M.
    Letai, Anthony G.
    BLOOD, 2014, 124 (21)
  • [5] Favorable patient survival after failure of venetoclax (ABT-199/GDC-0199) therapy for relapsed or refractory chronic lymphocytic leukemia
    Tam, Constantine
    Anderson, Mary Ann
    Ritchie, David
    Januszewicz, E. Henry
    Carney, Dennis
    Roberts, Andrew W.
    Seymour, John F.
    LEUKEMIA & LYMPHOMA, 2015, 56 : 107 - 108
  • [6] VENETOCLAX (ABT-199/GDC-0199) COMBINED WITH RITUXIMAB INDUCES DEEP RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
    Roberts, A. W.
    Ma, S.
    Brander, D.
    Kipps, T. J.
    Barrientos, J. C.
    Davids, M. S.
    Anderson, M. A.
    Choi, M.
    Tam, C.
    Magee, L.
    Kreutzer, J.
    Singh, R.
    Kim, J.
    Dimovski, B.
    Mason-Bright, T.
    Prine, B.
    Zhu, M.
    Humerickhouse, R. A.
    Seymour, J. F.
    HAEMATOLOGICA, 2015, 100 : 154 - 154
  • [7] VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE I SAFETY AND EFFICACY
    Kumar, S.
    Vij, R.
    Kaufman, J. L.
    Mikhael, J.
    Facon, T.
    Moreau, P.
    Amiot, M.
    Alzate, S.
    Morris, L.
    Ross, J.
    Dunbar, M.
    Zhu, M.
    Agarwal, S.
    Leverson, J.
    Enschede, S.
    Humerickhouse, R.
    Touzeau, C.
    HAEMATOLOGICA, 2015, 100 : 256 - 257
  • [8] Venetoclax (ABT-199/GDC-0199) combined with rituximab induces deep responses in patients with relapsed/refractory chronic lymphocytic leukemia
    Ma, Shuo
    Roberts, Andrew W.
    Brander, Danielle
    Kipps, Thomas J.
    Barrientos, Jacqueline C.
    Davids, Matthew S.
    Anderson, Mary Ann
    Choi, Michael
    Tam, Constantine
    Magee, Lisa
    Kreutzer, Jennifer
    Kim, Jennifer
    Dimovski, Belinda
    Mason-Bright, Tanita
    Prine, Betty
    Zhu, Ming
    Humerickhouse, Rod A.
    Seymour, John F.
    LEUKEMIA & LYMPHOMA, 2015, 56 : 21 - 21
  • [9] Favorable Patient Survival after Failure of Venetoclax (ABT-199/GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Tam, Constantine
    Anderson, Mary Ann
    Ritchie, David S.
    Januszewicz, E. Henry
    Carney, Dennis
    Roberts, Andrew W.
    Seymour, John F.
    BLOOD, 2015, 126 (23)
  • [10] BH3 profiling predicts clinical response in a phase II clinical trial of ABT-199 (GDC-0199) in acute myeloid leukemia
    Hogdal, Leah
    Chyla, Brenda
    McKeegan, Evelyn
    Leverson, Joel
    Potluri, Jalaja
    Falotico, Nancy
    Ricker, Justin
    Humerickhouse, Rod
    Mabry, Mack
    Foight, Glenna
    Keating, Amy
    Galinsky, Ilene
    Stone, Richard
    DeAngelo, Daniel
    Konopleva, Marina
    Letai, Anthony
    CANCER RESEARCH, 2015, 75
12345